Epirium Bio is developing a new class of therapeutics that stimulates muscle growth and strength as well as benefiting biogenesis in other tissues. The Company has clinical data in several degenerative muscle disease indications including Becker’s Muscular Dystrophy. Founded by George Schreiner MD PhD and Sundeep Dugar PhD.
Forty Seven developed an antibody against CD47, a “Don’t Eat Me” signal that regulates immune activity against many cancers. Founded by Irv Weissman MD (Director of the Stanford Stem Cell Institute) and Ravi Majeti MD PhD, Chair of Hematology at Stanford. The Company went public in 2018 and was acquired by Gilead in 2019 for $4.9 billion.
Kriya Therapeutics is a gene therapy company focused on major medical indications including Diabetes and Ophthalmologic diseases and with cutting edge manufacturing capabilities. Founded by Shankar Ramaswamy MD, Roger Jeffs PhD, and Fraser Wright PhD of Stanford.
Medikine is developing peptide-based cytokine activating drugs for use in cancer treatement. The Company is led by CEO Ron Barrett, PhD, past head of Xenoport.
Nutcracker Therapeutics is disrupting the manufacturing process for RNA Therapeutics by developing a “GMP factory in a box” to enable agile RNA drug development. Founded by Igor Khandros, past founder of Berkeley Lights.
Procyrion is a developing a medical device to treat Congestive Heart Failure and associated renal disease using an innovative implantable intravascular pump. Clinical studies begin in late 2020. Led by CEO Eric Fain, MD formerly of Abbott and St Jude Medical.